Zeria Pharmaceutical Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2016/02/03 | ¥14.93 | ¥32.35 | +116.7% |
| 2015/08/04 | ¥21.29 | ¥16.79 | -21.1% |
| 2015/05/07 | ¥20.34 | ¥-11.35 | -155.8% |
| 2015/02/04 | ¥27.12 | ¥19.67 | -27.5% |
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥25 | -47.9% |
| 2025 | ¥48 | +6.7% |
| 2024 | ¥45 | +2.3% |
| 2023 | ¥44 | +22.2% |
| 2022 | ¥36 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥59,533M | ¥68,383M | ¥75,725M | ¥87,311M |
| Gross Profit | ¥42,148M | ¥49,489M | ¥55,501M | ¥63,960M |
| Operating Income | ¥6,366M | ¥9,015M | ¥9,622M | ¥12,198M |
| Pretax Income | ¥6,037M | ¥7,610M | ¥9,966M | ¥13,071M |
| Net Income | ¥3,961M | ¥6,196M | ¥7,731M | ¥9,936M |
| EPS | ¥87.76 | ¥140.26 | ¥175.39 | ¥225.42 |
| Operating Margin | 10.69% | 13.18% | 12.71% | 13.97% |
| Balance Sheet | ||||
| Total Assets | ¥124,282M | ¥135,035M | ¥150,534M | ¥159,172M |
| Total Equity | ¥54,895M | ¥65,450M | ¥79,623M | ¥89,540M |
| Total Liabilities | ¥69,388M | ¥69,585M | ¥70,911M | ¥69,632M |
| Cash | ¥11,704M | ¥16,219M | ¥20,324M | ¥23,593M |
| Interest-bearing Debt | ¥52,229M | ¥49,432M | ¥46,228M | ¥41,164M |
| Equity Ratio | 44.17% | 48.47% | 52.89% | 56.25% |
| D/E Ratio | 0.95 | 0.76 | 0.58 | 0.46 |
| Cash Flow | ||||
| Operating CF | ¥8,951M | ¥13,157M | ¥12,184M | ¥12,922M |
| Investing CF | -¥2,893M | -¥2,575M | -¥3,952M | -¥1,051M |
| Financing CF | -¥4,841M | -¥7,415M | -¥8,124M | -¥7,757M |
| Free CF | ¥7,530M | ¥10,500M | ¥8,285M | ¥10,188M |
| Efficiency | ||||
| ROE | 7.22% | 9.47% | 9.71% | 11.10% |
| ROA | 3.19% | 4.59% | 5.14% | 6.24% |
Latest IR Information
-
Q1 Fiscal Year 2027 Financial Summary [Japan GAAP] (Consolidated)
Sales for the first quarter of fiscal year 2027 were 21.448 billion yen, up 10.1% YoY; operating income was 1.95 billion yen, up 28.3% YoY. Ordinary income was 1.432 billion yen, down 13.8% YoY, and net income attributable to owners...
Read more -
[Zeria Pharmaceutical Co., Ltd.] Notice of Appointment of Director Candidates | May 2026
Zeria Pharmaceutical Co., Ltd. plans to appoint director candidates at the shareholders' meeting scheduled for June 2026. New appointee includes Ms. Satomi Kojisato.
Read more -
Zeria Pharmaceutical|Dividend Increase and Shareholder Return Policy 2026 June
Zeria Pharmaceutical Co., Ltd. announced an increase in the year-end dividend for the fiscal year ending March 2026 to 25 yen per share, bringing the total annual dividend to 49 yen. The company emphasizes profits redistribution and maintains a policy...
Read more -
【Zeria Pharmaceutical】Financial Results for 2026 | Sales of ¥89.1 billion, Net Profit of ¥8.4 billion increase
Zeria Pharmaceutical's fiscal year ending March 2026 recorded sales of ¥89.1 billion (YoY +2.1%), net profit of ¥8.4 billion (down 14.9% YoY), with an increased overseas sales ratio of 59.3%. The company expects revenue and profit growth this term, with...
Read more -
Notice Regarding Executive Officer Personnel Changes
Effective April 9, 2026, Mr. Kenichi Suzuki is promoted from Executive Officer to Senior Executive Officer while continuing as General Manager of Corporate Planning.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,500
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.